Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Post Conference Perspectives: ASH 2024 : Episode 5
The Role of Posttransplant Cyclophosphamide in Patients With cGVHD
Sergio A. Giralt, MD, discusses how he uses cyclophosphamide to treat patients with chronic graft-vs-host disease (cGVHD), particularly in specific cases where other therapies may not be effective. He reviews the study design and methods of recent research investigating cyclophosphamide in cGVHD management, emphasizing its importance in optimizing treatment strategies.
EP: 1.The Pathophysiology of Chronic Graft-Vs -Host Disease (cGVHD) and the Role of CSF1R
EP: 2.Examining Axatilimab in the AGAVE-201 Trial For cGVHD
EP: 3.Exploring Combination Therapy with Ibrutinib and Rituximab in cGVHD
EP: 4.Discussing Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with cGVHD
Now Viewing
EP: 5.The Role of Posttransplant Cyclophosphamide in Patients With cGVHD
EP: 6.Main Conference Takeaways Regarding cGVHD Management
Video content above is prompted by the following:
- Which patients with chronic graft-vs-host disease (cGVHD) do you treat with cyclophosphamide in your clinical practice?
- What were this abstract’s study design and methods, and why was it important to investigate for cGVHD management?
Related Videos
Related Content
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Article
Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More
